Alembic Pharmaceuticals is currently trading at Rs. 555.25, up by 9.85 points or 1.81 % from its previous closing of Rs. 545.40 on the BSE.
The scrip opened at Rs. 541.55 and has touched a high and low of Rs. 561.60 and Rs. 540.00 respectively. So far 17297 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 709.30 on 23-Mar-2017 and a 52 week low of Rs. 492.25 on 27-Jun-2017.
Last one week high and low of the scrip stood at Rs. 561.60 and Rs. 522.15 respectively. The current market cap of the company is Rs. 10444.72 crore.
The promoters holding in the company stood at 72.68%, while Institutions and Non-Institutions held 14.00% and 13.32% respectively.
Alembic Pharmaceuticals has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Amlodipine Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Azor Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg, of Daiichi Sankyo Inc.
Olmesartan Medoxomil and Amlodipine Tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. According to IMS, these tablets have an estimated market size of $ 312 million for twelve months ending December 2016. The company now has a total of 61 ANDA approvals (53 final approvals and 8 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
